$HHSE in on any of this? HURRY! What If China's Money

New Post Public Reply Private Reply Replies (1) Message Board
kidzdmd
244
$HHSE in on any of this? HURRY!
What If China's Money Stream Stops Flowing to Hollywood?
6:00 AM PST 1/13/2017 by Patrick Brzeski
FACEBOOK
TWITTER
EMAIL ME
PRINT
COMMENTS

Illustration by: Kevin Hong

Beijing begins monitoring "irrational" investments in entertainment companies (even while Alibaba pledges $7.2 billion) as one deal falls apart and all eyes focus on Trump.
Chinese companies poured record amounts of capital into Hollywood in 2016 — a trend eagerly embraced by the U.S. film industry. Among the deals: Dalian Wanda Group acquired Legendary Entertainment for $3.5 billion and Dick Clark Productions for $1 billion; Alibaba made a major investment in Steven Spielberg's Amblin Entertainment; and Beijing-based Perfect World Pictures put $500 million into 50 films from Universal.

But tighter regulatory scrutiny and rising protectionism in the U.S. and China now have the industry questioning whether the deal flow could dry up in 2017. Already, there have been casualties.

Indie film player Voltage Entertainment, producer of The Hurt Locker and Dallas Buyers Club, surprised many in November when plans came to light for a provincial Chinese manufacturing firm to acquire the Los Angeles-based studio for $350 million. But within weeks, the firm, Anhui Xinke New Materials, revealed it was aborting the deal after failing to meet additional documentation requests from local regulators.

The agreement might have squeaked through if it had come a few months earlier. In early December, Beijing announced it was monitoring a pattern of "irrational" overseas investments in several sectors, particularly film, real estate and sports. In an effort to stem capital flight, which was seen as contributing to a devaluation of China's currency, regulators signaled that stricter oversight is on the way. According to a leaked draft of the new rules, Chinese officials said they would scrutinize offshore purchases of more than $1 billion if they were outside the investor's "core business" area. Insiders say deals well below that threshold already are being reviewed as well.

Ma Huateng
READ MORE
Hollywood Reporter's Top 10 China Power Players 2016
China's concerns are understood to be twofold: that some companies are disguising capital flight as foreign investment, while others are using high-profile entertainment purchases — a trendy sector among Chinese investors — as a short-term strategy to boost stock prices. "This increasing regulatory oversight will make it more difficult for 'concept deals' [Chinese companies acquiring businesses outside of their core business areas] to receive approval in 2017," says Peter Schloss, CEO of CastleHill Partners, a Beijing-based merchant bank focused on the media and entertainment industries.

In light of the new challenges, analysts predict Hollywood sellers will begin to demand larger breakup fees to test Chinese bidders' confidence in their ability to execute deals. But nobody knows how far-reaching the new regulations will be. "Some think that even the well-established entertainment companies may have trouble closing transactions," says Stanley Rosen, a USC professor of political science.

And in the U.S., the deals have caught the attention of Congress and the president-elect. On Nov. 30, incoming Senate minority leader Chuck Schumer said in a letter that the takeover of Hollywood companies by China firms should be examined more closely to determine whether they are being orchestrated to serve Chinese government interests.

At the same time, Donald Trump's appointment of hawkish economist Peter Navarro — author of such books as Death by China — to head a new White House National Trade Council inspired Chinese state media to warn of a potential "showdown with the U.S."

Yu Yongfu, CEO of Alibaba Digital Media and Entertainment Group
READ MORE
China's Alibaba to Invest $7.2B in Entertainment Over Three Years
Thus far, Hollywood dealmakers have been taking the long view, says Lindsay Conner, an attorney at Manatt with China experience. "People are watching the tweets and responses with interest, but there's no chill yet," he says. "There are protectionist winds blowing on both sides of the Pacific, but there are compelling business reasons for why Hollywood and China have a growing partnership — and those reasons remain."

And China's heavyweight conglomerates have shown little sign of moderating their expansionist ambitions. Alibaba's Jack Ma met Jan. 9 with Trump and pledged to create 1 million U.S. jobs, and Ma's new head of entertainment, Yu Yongfu, said in a memo that he planned to invest $7.2 billion in media during the next three years, with a focus on entertainment content. Yu was named CEO of Alibaba Digital Media and Entertainment Group in October and, he wrote in the memo, "I didn't come to play."

This story first appeared in the Jan. 20 issue of The Hollywood Reporter magazine. To receive the magazine, click here to subscribe.

Hannover House Inc. (HHSE) Stock Research Links

HHSE Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 184

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 138

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
Ping An's Bold Green Moves Ahead of APEC 2026

Updated Category News Views 0

Ping An's Pitch for Green: Talking the Talk and Walking the Walk? Well, here's something cooking in Shenzhen at the Ping An Finance Center—an international seminar championing green development initiatives. It's all buzz around Ping An Insurance (HKEX: 2318; SSE: 601318) flexing its green muscle, orchestrating conversations right before APEC 2026. Talk about timing....

Continue Reading
Likang's Bold Move: Cancer Immunotherapy at AD Summit

Updated Category News Views 134

Cancer Care Takes Center Stage Kicking off with a bang in Abu Dhabi, Likang Life Sciences has made a splash in the world of personalized cancer immunotherapy. The Abu Dhabi Future Health Summit 2026 served as the backdrop for this bold move, lighting up discussions with their AI-enabled innovations. Likang's showing at the Summit wasn't just another walk in the park—it...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 197

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
CSTS Unveils PremierX in NYC: A Bold Entertainment Move

Updated Category News Views 204

Welcome to the New Era of Entertainment Out of the blockbusters and into the open air, eh? On October 30, 2026, CSTS Enterprises flipped the New York skyline into a canvas for their grand kickoff of PremierXTM—a live entertainment brand poised to redefine how we gobble up our music, sport, and art. Now, there's a shot of adrenaline New Yorkers weren't exactly begging...

Continue Reading
Apalutamide Boosts Outlook for Prostate Cancer Treatment

Updated Category News Views 69

Fresh Findings on High-Risk Prostate Cancer Treatments In an industry that often feels like a game of chess, Johnson & Johnson's recent news unveils another one of their strategic moves with the announcement of breakthrough results from their Phase 3 PROTEUS substudy. Turns out, ERLEADA®, their apalutamide treatment, isn't just another pawn; it's a potential...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 173

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 154

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading
Bio-Thera's New Data: A Game Changer for NSCLC?

Updated Category News Views 337

A Fresh Look at Lung Cancer Solutions There's fresh meat on the oncology block, with Bio-Thera Solutions swinging for the fences at ESMO 2026, spotlighting promising Phase 2 clinical data for their combo treatment in first-line non-small cell lung cancer (NSCLC). If you're tuned into the biopharmaceutical sector or just keeping tabs on global health romps, this news sets...

Continue Reading

Top 5 Most Recently Viewed Articles

BerGenBio Welcomes First Patient in Lung Cancer Study

Updated Category News Views 202

BerGenBio Embarks on Promising Lung Cancer Trial BerGenBio ASA, a clinical-stage biopharmaceutical company dedicated to combating serious diseases through innovative therapies, has reached a significant milestone in its journey. The company has successfully included the first patient in its clinical trial, focusing on the cutting-edge AXL kinase inhibitor known as...

Continue Reading
CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform

Updated Category News Views 247

CIMG Inc. Introduces Tokenized Stock on FlowStocks Platform CIMG Inc. (NASDAQ: IMG), a dynamic group in the digital health and sales development sector, has officially launched its tokenized stock on the FlowStocks platform. This exciting development follows successful testing and represents a significant shift in how the company interacts with its investors. The new...

Continue Reading
Exploring the Impact of New SEC Leadership on Cryptocurrency

Updated Category News Views 179

New Era for Cryptocurrency Under SEC Leadership The recent changes at the Securities and Exchange Commission (SEC) under new leadership signal a transformative period for the cryptocurrency market. These developments could reshape the regulatory landscape, offering clarity and direction for investors and companies involved in the digital asset space. Understanding the...

Continue Reading
Shytoshi Kusama Transitions Roles: Shiba Inu's New Direction

Updated Category News Views 190

Shytoshi Kusama Transitions to New Leadership Role Shytoshi Kusama, the driving force behind the Shiba Inu ecosystem, has made a significant change by stepping down from his role as the lead visionary. This pivotal shift marks a transition to the position of lead ambassador, as he aims to spearhead global adoption more effectively. The Shift in Leadership Announcing his...

Continue Reading
BASF Shares Fall Following Proposed Dividend Cuts to Shareholders

Updated Category News Views 281

BASF (ETR:BASFN) just took a hit on its stock price after announcing some major shifts in its dividend policy. Shares plummeted by 2.9% to €44.035, all thanks to the company's new proposed minimum annual dividend of €2.25 per share for the upcoming 2024 business year. That’s a stark drop from the previous €3.40 per share they dished out in 2023—talk about making...

Continue Reading